Melatonin Treatment for Newborn Infants With Moderate to Severe Hypoxic Ischemic Encephalopathy



Status:Withdrawn
Conditions:Peripheral Vascular Disease, Infectious Disease, Neurology, Psychiatric
Therapuetic Areas:Cardiology / Vascular Diseases, Immunology / Infectious Diseases, Neurology, Psychiatry / Psychology
Healthy:No
Age Range:Any
Updated:4/21/2016
Start Date:April 2014
End Date:November 2018

Use our guide to learn which trials are right for you!

During the birth process certain conditions can cause oxygen delivery and/or blood flow to
the baby's brain to become interrupted. This can cause permanent brain damage. Brain damage
occurs in two phases. The first occurs at the time of injury when brain cells in the
affected area 'die'. There is nothing that can be done about this. The second phase of
injury occurs over the next few days. This second phase is caused by inflammation and
release of toxic chemicals from the injured site. Cooling the baby to a temperature of 92.5°
F, for 3 days has been shown to reduce the second phase of injury and bran death. All babies
will receive the benefit of cooling. Although cooling helps it does not completely stop the
second phase of injury.

Melatonin is a naturally occurring hormone that is produced by the brain, and helps regulate
the sleep-wake cycle. It has the potential to stop the second phase of brain injury by
inhibiting inflammation and release of toxic chemicals. The reason for this research is to
find out if melatonin can or cannot improve the outcome of babies with this kind of brain
damage. Every baby enrolled in the study has a 50:50 chance of getting melatonin. A total of
six doses of medicine will be given. The baby's brain function will be assessed by an EEG,
brain oxygen monitoring, and a neurologic examination at 18 months of life. All of these are
routinely used as part of standard care for patients with this kind of problem. The only
difference is that half the babies enrolled in the study will get the drug called melatonin
and the other half will receive placebo. The dose of melatonin being used in the study is
higher than the amount normally produced by the body. No side-effects of this dose have been
reported in other research studies using melatonin in newborn and premature babies.

This is a double-blind randomized study. All babies less than eight hours old, admitted to
the NICU at Cardinal Glennon Children's Medical Center, with moderate to severe HIE that
qualify for whole body cooling will be eligible for enrollment in the study. Whole body
cooling is part of standard treatment for babies with moderate to severe HIE, and the
criteria for diagnosis and cooling are well established. After consent is obtained babies
will be randomly assigned to melatonin treatment or control groups (standard treatment)
using a 4-block randomization design, by opening a sealed opaque sequentially numbered
envelope by the study pharmacist. A log of assignments will be maintained by the study
pharmacist. The clinical team will be blinded as to the assignment. Patients assigned to
melatonin treatment will receive 40 mg melatonin (PureBulk, CA, USA) in 5 mL of vehicle
(1:90 mix ethanol/saline) every 8 hours for a total of six doses. Patients assigned to the
control group will receive 5 mL of vehicle only every 8 hours for a total of six doses. All
doses will be administered via a nasogastric tube by the nurse assigned to the patient.
Placement of a nasogastric tube is part of standard care for babies with HIE. Administration
of the first dose within eight hours of life is mandatory for the study.

EEG analysis is part of standard neurologic evaluation for patients with HIE, and is done
once the patient has been rewarmed to normal body temperature (by 78-80 hours after starting
whole body cooling). A 24 hour multichannel video-EEG (Nihon Kohden 9100A, Nihon Kohden USA
Inc.) using the 10-20 system of electrode placement modified for neonates will be performed
between 80 and 100 hours after initiation of the cooling protocol. The duration of each
seizure will be added together for the entirety of the recording to obtain the seizure
burden (total seizure time).

Anticonvulsant treatment will assessed at the time of discharge whether the patient is on
any, one, or more anticonvulsants.

Cerebral tissue oxygenation (rSO2) will be monitored non-invasively by applying the NIRS
probe to the forehead and attaching it to the INVOS monitor (Somanetics, MI, USA). The probe
is very similar to the oxygen saturation oximeter probe that is routinely used in newborns.
Cerebral tissue oxygenation will be continuously monitored until re-warming is complete.
Data will be collected at the start of monitoring and then every six hours.

A brain MRI is not required for the study, but if it is obtained then the results may be
included in the data collected.

Inclusion Criteria:

- Infants with moderate to severe hypoxic ischemic encephalopathy ≥36 weeks

- First dose of study drug given within 8 hours of birth

Exclusion Criteria:

- Major chromosomal or congenital defects
We found this trial at
1
site
?
mi
from
St. Louis, MO
Click here to add this to my saved trials